Form D · Pharmaceuticals

Melt Pharmaceuticals, Inc.

Brentwood, TN · CIK 0001767398

Offering snapshot reported Apr 8, 2024 · SEC filing

Reported sold
$42.3M
Offering amount: $47.8M
Investors reported
309
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 28, 2023
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$21.1M$42.3MAug 11, 2023: $1,808,970.00Aug 11, 2023Sep 12, 2023: $10,594,468.00Oct 13, 2023: $17,145,928.00Nov 13, 2023: $19,551,717.00Dec 11, 2023: $20,181,312.00Jan 9, 2024: $38,980,960.00Feb 12, 2024: $39,485,520.00Mar 11, 2024: $41,552,780.00Apr 8, 2024: $42,292,450.00Apr 8, 2024

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$39,485,520 → $42,292,450
  • Reported investors287 → 309

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 8, 2024Amendment$42,292,450$2,806,930vs Feb 12, 2024309SEC filing
Mar 11, 2024Amendment$41,552,780$2,067,260vs Feb 12, 2024300SEC filing
Feb 12, 2024Amendment$39,485,520$504,560vs Jan 9, 2024287SEC filing
Jan 9, 2024Amendment$38,980,960$18,799,648vs Dec 11, 2023276SEC filing
Dec 11, 2023Amendment$20,181,312$629,595vs Nov 13, 2023272SEC filing
Nov 13, 2023Amendment$19,551,717$2,405,789vs Oct 13, 2023264SEC filing
Oct 13, 2023Amendment$17,145,928$6,551,460vs Sep 12, 2023215SEC filing
Sep 12, 2023Amendment$10,594,468$8,785,498vs Aug 11, 2023116SEC filing
Aug 11, 2023Initial$1,808,970No comparison37SEC filing
Apr 5, 2019Amendment$11,435,000$645,000vs Feb 13, 2019165SEC filing
Feb 13, 2019Initial$10,790,000No comparison152SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$1.79M
Finders' fees
$0
Form D file number
021-489452
The Total Offering Amount was increased to account for the issuance of securities to settle certain outstanding indebtedness.
In addition to the Sales Commissions noted above, the placement agent will receive compensation warrants to purchase up to 84,345 shares.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Newbridge Securities CorporationNone

Source: Form D, filed Apr 8, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mark Baum Director
John Berdahl Director
Andrew Boll Director
Larry Dillaha Director, Executive
Gregory Madison Director, Executive
Brad Osborne Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
5511 Virginia Way Suite 300
Brentwood, TN, 37027